1-5 of 5
Arturo Chiti, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Longitudinal Assessment of Circulating Tumor Mutational Burden Using a Next-Generation Sequencing Cancer Gene Panel: A Potential Biomarker of Response to Programmed Cell Death 1 (PD-1) Blockade in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Martina Di Trani, Ettore Rizzo, Silvia Locatelli, PhD, Fabrizio Marino, MD, Vanessa Cristaldi, PhD, Valeria Spina, PhD, Alessio Bruscaggin, PhD, Federica De Paoli, PhD, Giuseppa Careddu, Marcello Rodari, MD, Margarita Kirienko, MD, Eleonora Calabretta, MD, Massimo Magagnoli, MD, Lucia Morello, MD, Francesca Ricci, MD, Arturo Chiti, MD, Armando Santoro, Stefan Hohaus, MD, Davide Rossi, MD PhD, Carmelo Carlo-Stella, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 131.
https://doi.org/10.1182/blood-2019-131096
Published: 2019
Journal Articles

Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate

Armando Santoro, MD, Luca Castagna, MD, Massimo Magagnoli, MD, Stefania Bramanti, MD, Jacopo Mariotti, MD, Rita Mazza, MD, Lucia Morello, MD, Francesca Ricci, MD, Barbara Sarina, MD, Chiara De Philippis, MD, Simona Sica, MD, Marcello Rodari, MD, Martina Sollini, MD, Margarita Kirienko, MD, Laura Giordano, Arturo Chiti, MD, Paolo Corradini, MD, Carmelo Carlo-Stella, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2185.
https://doi.org/10.1182/blood-2018-99-118127
Published: 2018
Journal Articles

Bendamustine in Combination with Gemcitabine and Vinorelbine (BEGEV) Is an Effective Regimen for Heavily Pretreated, Relapsed/Refractory Hodgkin Lymphoma Patients: A Multicenter, Retrospective Real-World Study

Antonio Russo, MD, Alessandro Pulsoni, MD, Simonetta Viviani, MD, Francesca Ricci, MD, Rita Mazza, MD, Massimo Magagnoli, MD, Lucia Morello, MD, Francesco Landi, MD, Anna Guidetti, MD, Michele Merli, MD, Marcello Rodari, MD, Alessandra Serrao, MD, Giorgia Annechini, MD, Andrea Nervini, MD, Laura Giordano, Luca Castagna, MD, Francesco Passamonti, MD, Arturo Chiti, MD, Paolo Corradini, MD, Armando Santoro, MD, Carmelo Carlo-Stella, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1655.
https://doi.org/10.1182/blood-2018-99-115313
Published: 2018
Journal Articles

Dimension of Residual CT Scan Mass in Hodgkin's Lymphoma (HL) Is a Negative Prognostic Factor in Patients with PET Negative After Chemo+/− Radiotherapy

Massimo Magagnoli, Katia Marzo, MD, Monica Balzarotti, Marcello Rodari, Rita Mazza, Laura Giordano, MD, Sara Gandolfi, MD, Stefania Bramanti, Antonella Anastasia, MD, Fabio Romano Lutman, MD, Arturo Chiti, MD, Armando Santoro
Journal: Blood
Blood (2011) 118 (21): 93.
https://doi.org/10.1182/blood.V118.21.93.93
Published: 2011
Journal Articles

Pretransplatation PET as Major Prognostic Discriminant in IGEV (ifosfamide, gemcitabine, vinorelbine and prednisone) Treated Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL).

Rita Mazza, MD, Stefano Luminari, Massimo Magagnoli, MD, Michele Spina, MD, Teodoro Chisesi, MD, Antonio Pinto, MD, Massimo Federico, MD, Antonella Anastasia, MD, Arturo Chiti, MD, Mariagrazia Michieli, MD, Francesco Angrilli, MD, Luca Castagna, Giampaolo Marcacci, Laura Giordano, PhD, Umberto Tirelli, MD, Armando Santoro, Monica Balzarotti
Journal: Blood
Blood (2009) 114 (22): 3707.
https://doi.org/10.1182/blood.V114.22.3707.3707
Published: 2009